FDA/Kaiser Study Questions Merck's Vioxx Cardiovascular Safety
This article was originally published in The Pink Sheet Daily
Executive Summary
Vioxx at doses greater than 25 mg/day is associated with increased risk of acute myocardial infarction and sudden cardiac death, study says. Pfizer's Celebrex had a lower risk of cardiovascular events, the study finds.
You may also be interested in...
Celebrex Cardiovascular Safety Supported In FDA/Kaiser Study
FDA releases data from COX-2 cardiovascular safety study that was included in a Sept. 30 internal memo to Office of Drug Safety Director Seligman. The study shows Celebrex patients have lower cardiovascular safety risk compared to remote NSAID users.
Celebrex Cardiovascular Safety Supported In FDA/Kaiser Study
FDA releases data from COX-2 cardiovascular safety study that was included in a Sept. 30 internal memo to Office of Drug Safety Director Seligman. The study shows Celebrex patients have lower cardiovascular safety risk compared to remote NSAID users.
FDA Memo Discussed Pulling Vioxx Based On HMO Study
An FDA internal memo discusses pulling Merck's Vioxx (rofecoxib) based on the results of a retrospective study sponsored by the agency and Kaiser Permanente